Table 4.
Use and duration of monotherapies with in vitro efficacy and risk for relapse
| Administered Antibiotic with Documented In Vitro Efficacy | No. of Episodes | Total Duration of Administration (Days; Mean ± SD [P]) | % (P) Followed by Relapsea |
|---|---|---|---|
| First-generation cephalosporin | 26 | 15 ± 7 (0.47) | 23 (0.02) |
| Glycopeptide | 44 | 16 ± 5 (0.25) | 9 (0.77) |
| Ceftazidime | 45 | 14 ± 5 (0.78) | 4 (0.73) |
| Aminoglycoside | 5 | 19 ± 3 | 0 (0.44) |
Antibiotic therapies with no significant frequency of use not shown.
a
Statistical significance indicates difference compared with all other monotherapies.